Adjuvant treatment for endometrial cancer: efficacy, toxicity and quality of life

Boer, S.M. de

AUTHOR AFFILIATIONS

The Netherlands

Leiden University Medical Center, Leiden
Department of Radiation Oncology
Stephanie M. de Boer, Bastiaan G. Wortman, Remi A. Nout, Carien L. Creutzberg

Department of Pathology
Tjalling Bosse, Vincent T.H.B.M. Smit

Department of Medical Statistics
Hein Putter

University Medical Center Utrecht
Department of Radiation Oncology
Ina M. Jürgenliemk-Schulz

Medisch Spectrum Twente, Enschede
Department of Radiation Oncology
Jan J. Jobsen

Maastricht University Medical Centre, Maastricht
Department of Radiation Oncology
Ludy C.H.W. Lutgens

Department of Obstetrics and Gynaecology and GROW - School for Oncology and Developmental Biology
Roy F. Kruitwagen

Radiotherapy Group Arnhem
Elzbieta M. van der Steen-Banasik

ErasmusMC-Daniel den Hoed Cancer Center, Rotterdam
Department of Radiation Oncology
Jan Willem M. Mens

Radiotherapy Institute Friesland, Leeuwarden
Annerie Slot

Radiotherapy Group Deventer
Marika C. Stenfert Kroese, Sandrine M.G. van de Pol

Netherlands Comprehensive Cancer Organisation
Research Department Eindhoven and Center of Research on Psychology in Somatic Diseases
Simone Oerlemans

Comprehensive Cancer Center The Netherlands, Leiden
Karen W. Verhoeven-Adema

University Medical Center Groningen, Groningen
Department of Gynaecologic Oncology
Hans W. Nijman

Department of Pathology
Harry Hollema

Department of Radiation Oncology
Elizabeth Pras

Radboudumc, Nijmegen
Department of Medical Oncology
Petronella B. Ottevanger

Department of Radiation Oncology
An Snyers

Amsterdam University Medical Center, AMC
Department of Radiation Oncology
Henrike Westerveld

Haaglanden Medical Center
Department of Radiation Oncology
Tanja C. Stam

Netherlands Cancer Institute, Amsterdam
Department of Radiation Oncology
Baukelien van Triest, Monique Bloemers

Radiotherapy Institute Verbeeten, Tilburg
Karin A.J. de Winter

Catharina Hospital, Eindhoven
Department of Radiation Oncology
Hetty A. van den Berg

United Kingdom

Barts Health NHS Trust, London
Department of Clinical Oncology
Melanie E. Powell

Department of Cellular Pathology
Naveena Singh, Munaib N. Chowdhury

Cancer Research UK and UCL Cancer Institute, London
Jonathan A. Ledermann, Amanda Feeney

University of Manchester, Manchester
Institute of Cancer Sciences
Henry C. Kitchener

Central Manchester Hospitals NHS Foundation Trust, Manchester Royal Infirmary, Manchester
Department of Pathology
Godfrey Wilson

Australia & New Zealand

Peter MacCallum Cancer Centre, Melbourne, VIC
Division of Cancer Medicine
Linda Mileshkin

Division of Radiation Oncology
Pearly Khaw

Auckland City Hospital, Auckland
Department of Radiation Oncology
Susan Brooks

Liverpool Cancer Therapy Centre, Liverpool
Department of Radiation Oncology
Viet Do

Royal Women's Hospital, Victoria
Department of Anatomical Pathology
Jan Pyman

The University of Sydney, Sydney
NHMRC Clinical Trials Centre
Ilka Kolodziej

Italy

Città della Salute and S Anna Hospital, University of Turin, Turin
Department of Surgical Sciences, Gynecologic Oncology
Dionyssios Katsaros

ASST-Lecco, Ospedale AManzoni, Lecco
Division of Radiation Oncology
Alessandro Colombo, Romerai D'Amico

A.O.U. Città della Salute e della Scienza di Torino, Turin
Department of Oncology – Radiotherapy
Sergio Gribaudo

San Gerardo Hospital, University of Milano-Bicocca, Monza
Department of Obstetrics and Gynecology, Gynecologic Oncology Unit
Andrea Lissoni

European Institute of Pathology, Milan
Division of Pathology and Laboratory Medicine
Silvestro Carinelli

Canada

University of Sherbrooke, Sherbrooke, QC
CCTG, Department of Obstetrics and Gynaecology
Paul Bessette

Princess Margaret Cancer Centre, Toronto
CCTG, Radiation Medicine Program
Anthony Fyles

Hôpital Notre-Dame de Montreal, Montreal, QC
Department of Gynaecologic Oncology
Diane Provencher

Western University, London
Department of Pathology and Laboratory Medicine
Meg C.M. McLachlin

France

Institut Gustave Roussy, Villejuif
Department of Radiation Oncology
Christine Haie-Meder

Department of Pathology
Pierre Duvillard

Centre Hospitalier Régional Universitaire de Besançon, Besançon
Department of Radiation Oncology
Marie-Helene Baron

Centre Henri Becquerel, Rouen
Department of Radiation Oncology
Chantal Hanzen

PORTEC-3 PARTICIPATING GROUPS AND CENTRES

PORTEC-3 Independent data monitoring committee:

L.V.A.M. Beex, N. James, M.J.M. Olofsen-van Acht, W. Parulekar, W.L.J. van Putten, D. Rischin, J. Yarnold (chair)

PORTEC-3 trial statistician: H. Putter

List of participating countries and centres (listed in order of patients recruited)

United Kingdom: 184 patients (177 evaluable)

Study Coordinators: M. Powell (P.I.), London; H. Kitchener, Manchester; J. Ledermann, London

Group coordinating trial centre: Cancer Research UK and UCL Cancer Trials Centre, London

Trial pathologists: N. Singh, London; G. Wilson, Manchester

Participating centres and principal investigator(s) (number of patients):

London-Barts Health NHS Trust (M. Powell, 23); London-University College London Hospitals NHS Foundation Trust (M. McCormack, 15); Bebington, Wirral-The Clatterbridge Cancer Centre NHS Foundation Trust (K. Whitmarsh, K. Hyatt, 12); Wolverhampton-The Royal Wolverhampton NHS Trust (R. Allerton, 11); Cambridge-Cambridge University Hospitals NHS Foundation Trust (L.T. Tan, M. Iddawela, D. Gregory, S. Ayres, 11); Leicester-Leicester Royal Infirmary (P. Symonds, 10); Northwood-Mount Vernon Cancer Centre (P. Hoskin, 10); Middlesborough-The James Cook University Hospital (A. Rathmell, M. Adusumalli, 9); Nottingham-Nottingham City Hospital (S. Chan, A Anand, 9); Norwich-Norfolk and Norwich University Hospitals NHS Foundation Trust (R. Wade, 8); Guildford-Royal Surrey County Hospital (A. Stewart, 6); Newcastle Upon Tyne-Freeman Hospital (W. Taylor, 6); Brighton-Brighton & Sussex University Hospitals NHS Trust (K. Lankester, 5); Coventry-University Hospital Coventry (C. Irwin, M. Hocking, 5); Taunton-Musgrove Park Hospital (P. Jankowska, D. Milliken, C. Barlow, 5); Cheltenham-Cheltenham General Hospital (A. Cook, R. Counsell, 4); Exeter-Royal Devon & Exeter Hospital (P. Bliss, A. Hong, 4); Lincoln-Lincoln County Hospital (M. Panades, 4); Romford-Queens Hospital (M. Quigley, 4); Manchester-The Christie NHS Foundtion Trust (S. Davidson, 3); Northampton-Northampton General Hospital NHS Trust (C. Mak, 3); Preston-Royal Preston Hospital (A. Hindley, 3); Truro-Royal Cornwall Hospitals NHS Trust (A. Thomson, 3); Sheffield-Weston Park Hospital (S. Pledge, J. Martin, 2); Shrewsbury-Royal Shrewsbury Hospital (S. Awwad, A. Zachariah, 2); Carlisle-North Cumbria University Hospitals NHS Trust (S. Singhal, 1); Colchester-Essex County Hospital (A. Lamont, 1); London-Guy's and St. Thomas' NHS Foundation Trust (A. Winship, A. Montes, V. Mullassery, 1); London-Hammersmith Hospital - Imperial College Healthcare NHS Trust (A. Taylor, 1); Poole-Poole Hospital NHS

Foundation Trust (V. Laurence, M. Flubacher, 1); Reading-Royal Berkshire Hospital (H. O'Donnell, 1); Stoke-on-Trent-Royal Stoke University Hospital (R. Bhana, S. Lupton, 1)

The Netherlands: 145 patients (138 evaluable)

Study Coordinators: C.L. Creutzberg (C.I.), Leiden; R. Kruitwagen, Maastricht; H. Nijman, Groningen; N. Ottevanger, Nijmegen
Group coordinating trial centre: Netherlands Comprehensive Cancer Organisation (IKNL), Leiden
Trial pathologists: H. Hollema, Groningen; V.T. Smit, Leiden
Participating centres and principal investigator(s) (number of patients):
University Medical Center Utrecht (I.M. Jurgenliemk-Schulz, 20); Maastro Clinic, Maastricht (L.C.H.W. Lutgens, 17); University Medical Center Groningen (E. Pras, 15); Leiden University Medical Center (C.L. Creutzberg, R. Nout, 15); University Medical Center Radboud, Nijmegen (J.W.H. Leer, A. Snyers, 11); Academic Medical Center, Amsterdam (A.L.J. Uitterhoeve, G.H. Westerveld, 9); Medical Spectre Twente, Enschede (J.J. Jobsen, 9); Radiotherapy institute Friesland, Leeuwarden (A. Slot, 9); Erasmus Medical Center Rotterdam (J.W.M. Mens, 8); Medical Center Haaglanden/ Radiotherapy Centre West (T.C. Stam, P.C.M. Koper, 7); Netherlands Cancer Institute, Amsterdam (B. van Triest, 6); Radiotherapy Group, Arnhem (E.M. van der Steen-Banasik, 6); Radiotherapy Institute Verbeeten, Tilburg (K.A.J. de Winter, 6); Radiotherapy Group, Deventer (S. van de Pol, 3); Catharina Hospital, Eindhoven (H.A. van den Berg, 3); VU Medical Centre, Amsterdam (O.W.M. Meijer, 1)

Australia & New Zealand: 122 patients (118 evaluable)

ANZGOG Study Coordinators: L. Mileshkin (P.I.) Melbourne; M. Quinn, Melbourne; P. Khaw Melbourne; I.Kolodziej, Sydney
Group coordinating trial centre: NHMRC Clinical Trials Centre, Sydney
Trial pathologist: J.Pyman, Melbourne
Participating centres and principal investigator(s) (number of patients):
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia (L. Mileshkin, P.Khaw; 31); Monash Cancer Centre (Monash Medical Centre), East Bentleigh, Victoria, Australia (P. Khaw/G. Goss, 20); Westmead Hospital, Wentworthville, NSW, Australia (G. Wain, 15); Auckland City Hospital , Auckland, New Zealand (S. Brooks, 13); Wellington Blood & Cancer Centre, Wellington, New Zealand (C. Johnson, 11); Calvary Mater Newcastle, Newcastle, Australia (A. Capp, 8); Christchurch Hospital, Canterbury, New Zealand (M. Vaughan, 4); Royal Hobart Hospital, Hobart, Tasmania, Australia (P. Blomfield, 3); Palmerston North Hospital, Palmerston North, New Zealand (C. Hardie, 3); Royal North Shore Hospital, St Leonards, NSW, Australia (M. Stevens, 3); Waikato Hospital, Hamilton, New Zealand (M. Kuper, 2); Royal Brisbane &Women's Hospital, Brisbane, QLD, Australia(R.

Cheuk, 2); Liverpool Hospital, Liverpool, NSW, Australia (S. Vinod, 2); Mater Hospital Brisbane , South Brisbane, QLD, Australia(C. Shannon/J. Ramsay, 2); Wollongong Hospital, Wollongong, NSW, Australia (A. Glasgow, 2); Townsville Hospital, Townsville, QLD, Australia (S. Hewitt, 1)

Italy: 103 patients (98 evaluable)

MaNGO Study Coordinators: R. Fossati (P.I.) Milano; D. Katsaros, Torino; A. Colombo, Lecco
Group coordinating trial centre: Istituto di Ricerche Farmacologiche Mario Negri, Milano
Trial pathologists: S. Carinelli, Milano; C. Di Tonno, Milano
Participating centres and principal investigator(s) (number of patients):
Torino - S. Anna Hospital (S. Gribaudo, M. Mitidieri, 33); Lecco - Ospedale A. Manzoni (R. D'Amico, 24); Monza - S. Gerardo Hospital (S. Meregalli, A. A. Lissoni, 16); Torino - Ospedale Umberto I (A. Ferrero, 7); Padova – Istituto Oncologico Veneto / Mirano, Venezia – Azienda ULSS 13 (L. Corti, G. Artioli, 6); Varese - H. Del Ponte University of Insubria (C. Apolloni, 4); Ravenna - Ospedale S. Maria delle Croci (D. Turci, 4); Brescia – Spedali Civili (G. Tognon, 2); Como – ASST Lariana Ospedale S. Anna (E. Bianchi, 2); Meldola - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (E. Bianchi, 2); Genova – IRCCS San Martino IST (M. Bruzzone, 1); Milano - ASST Grande Ospedale Metropolitano Niguarda (S. Siena, 1); Palermo – AOR Villa Sofia-Cervello (N. Varsellona, 1)

Canada: 65 patients (65 evaluable)

CCTG Study Coordinators: A. Fyles Toronto, Ontario; P. Bessette, Sherbrooke, Quebec
Group coordinating trial centre: Canadian Cancer Trials Group, Kingston, Ontario
Trial pathologist: M. McLachlin, London, Ontario
Participating centres and principal investigator(s) (number of patients):
Sherbrooke-Centre Hosp. Universitaire de Sherbrooke (P. Bessette, 18); Montreal-Hopital Notre-Dame de Montreal (D. Provencher, 11); Calgary-Tom Baker Cancer Centre (P. Ghatage, 9); Halifax-Queen Elizabeth II Health Sciences Centr (P. Rittenberg, 8); Montreal-McGill Oncology Montreal (L. Souhami, 7); Toronto-Sunnybrook Health Sciences Centre (G. Thomas, 7); Quebec-Hotel-Dieu de Quebec (M. Plante, 2); London-London Health Sciences Centre (A. Hammond, 1); St John's-Dr. H. Bliss Murphy Cancer Centre (P. Power, 1); Toronto-Princess Margaret Hospital (A. Fyles, 1)

France: 67 patients (64 evaluable)

FEDEGYN Study Coordinator: Chr. Haie-Meder (P.I.) Paris
Group coordinating trial centre: UNICANCER, Paris
Trial pathologist: P. Duvillard, Paris
Participating centres and principal investigator(s) (number of patients):

Besancon-Hopital Jean Minjoz (M-H Baron, 10); Rouen-Centre Henri Becquerel (Hanzen, 9); Saint Herblain-Centre Rene Gauducheau (D. Berton-Rigaud, 8); Limoges-CHU Limoges (Pr. N. Tubiana-Mathieu, 6); Bordeaux-Institut Bergonie (L. Thomas, 5); Reims-Institut Jean Godinot (A. Savoye, S. Maillard, 5); Dijon-Centre Georges Francois Leclerc (K. Peignaux, 4); Paris/ Villejuif-Institut Gustave Roussy (C. Haie Meder, 4); Clermont-Ferrand-Centre Jean Perrin (C. Benoit, 3); Montpellier-Centre Val d'Aurelle (C. Kerr, 3); Toulouse Cedex-Institut Claudius Regaud (L. Gladieff, 3); Caen-Centre Francois Baclesse (D. Lerouge, 2); Nice Cedex-Centre Antoine Lacassagne (P. Follana, 2); Marseille-Institut Paoli Calmettes (M. Cappiello, 1); Strasbourg-Centre Paul Strauss (T. Petit, 1); Tours Cedex-CHU de Tours - Hopital Bretonneau (I. Barillot, 1)

LIST OF PUBLICATIONS AND CONFERENCE PRESENTATIONS

Publications

de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, R. D'Amico, A. Fyles, M.H. Baron, I.M. Jurgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, G. Wilson, S. Brooks, S. Gribaudo, D. Provencher, C. Hanzen, R.F. Kruitwagen, V. Smit, N. Singh, V. Do, A. Lissoni, R.A. Nout, A. Feeney, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg; Patterns of recurrence and updated survival outcomes in the randomised PORTEC-3 trial of adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer; Lancet Oncol. Epub 22 July 2019

de Boer, S.M., R.A. Nout, C.L. Creutzberg; Adjuvante behandeling van hoog-risico endometriumcarcinoom: update van recente gerandomiseerde trials; NTVO. Accepted.

de Boer S.M., R.A. Nout, T. Bosse, C.L. Creutzberg; Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions; Expert Rev Anticancer Ther. 2019 Jan;19(1):51-60. doi: 10.1080/14737140.2019.1531708. Epub 2018 Oct 24.

Wortman, B.G., C.L. Creutzberg, H. Putter, I.M. Jurgenliemk-Schulz, J.J. Jobsen, L. Lutgens, E.M. van der Steen-Banasik, J.W.M. Mens, A. Slot, M.C. S. Kroese, B. van Triest, H.W. Nijman, E. Stelloo, T. Bosse, **S.M. de Boer**, W.L.J. van Putten, V. Smit, R.A. Nout; PORTEC Study Group; Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy; Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

Nout, R.A., M.E. Powell, **S.M. de Boer**, C.L. Creutzberg (2018) Investigators' response. Lancet Oncol, 19, 602.

de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, I.M. Jurgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, G. Wilson, S. Brooks, S. Carinelli, D. Provencher, C. Hanzen, L. Lutgens, V. Smit, N. Singh, V. Do, R. D'Amico, R.A. Nout, A. Feeney, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg; Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncology 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2.

de Boer, S.M., B.G. Wortman, T. Bosse, M.E. Powell, N. Singh, H. Hollema, G. Wilson, M.N. Chowdhury, L. Mileshkin, J. Pyman, D. Katsaros, S. Carinelli, A. Fyles, C.M. McLachlin, C. Haie-Meder, P. Duvillard, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, V. Smit; Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Annals of Oncology 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753

de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, R.A. Nout, K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg; Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology 2016; 17(8): 1114-26. http://dx.doi.org/10.1016/S1470-2045(16)30120-6.

de Boer, S.M., R.A. Nout, I.M. Jurgenliemk-Schulz, J.J. Jobsen, L.C. Lutgens, E.M. van der Steen-Banasik, J.W. Mens, A. Slot, M.C. Stenfert Kroese, S. Oerlemans, H. Putter, K.W. Verhoeven-Adema, H.W. Nijman, C.L. Creutzberg; Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial; Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):797-809

de Graaf, F.R., J.E. van Velzen, **S.M. de Boer**, J.M. van Werkhoven, L.J. Kroft, A. de Roos, A. Sieders, G.J. de Grooth, J.W. Jukem.a, J.D. Schuijf, J.J. Bax, M.J. Schalij, E.E van der Wall; Non-invasive computed tomography coronary angiography as a gatekeeper for invasive coronary angiography Int J Cardiovasc Imaging. 2012 May 11

van Werkhoven J.M.* MSc, **S.M. de Boer***, J.D. Schuijf, F. Cademartiri, E. Maffei, J.W. Jukema, M.J. Boogers, L.J. Kroft, A. de Roos, J.J. Bax; Impact of Clinical Presentation and Pre-Test Likelihood on the Relation between Calcium Score and Computed Tomography Coronary Angiography; Am J Cardiol. 2010 Dec 15;106(12):1675-9. Epub 2010 Nov 4)
*Dr. van Werkhoven and Ms. de Boer contributed equally to this work.

Conference presentations

American Society for Radiation Oncology (ASTRO) annual meeting 2019 (oral presentation)
de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, I.M. Jürgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, V.T. Smit, R.A. Nout, H. Putter, C.L.

Creutzberg; Patterns of recurrence and survival in the randomized PORTEC-3 trial of chemoradiotherapy for high-risk endometrial cancer.

Gynaecology congress of the Dutch Society of Obstetrics and Gynaecology (NVOG) 2019 (oral presentation)
de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, I.M. Jürgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, V.T. Smit, R.A. Nout, H. Putter, C.L. Creutzberg; Update of survival outcomes in the PORTEC-3 trial

European Society Radiation Oncology (ESTRO) annual meeting 2018 (oral presentation)
de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, I.M. Jürgenliemk-Schulz, H.C. Kitchener, H.W. Nijman, G. Wilson, I. Kolodziej, S. Carinelli, L.C.H.W. Lutgens, V.T.H.B.M. Smit, N. Singh, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg; OC-0323: Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer.

European Congress of Pathology (ECP) annual meeting 2017 (oral presentation)
de Boer, S.M., B.G. Wortman, T. Bosse, M.E. Powell, N. Singh, H. Hollema, G. Wilson, M.N. Chowdhury, L. Mileshkin, J. Pyman, D. Katsaros, S. Carinelli, A. Fyles, C.M. McLachlin, C. Haie-Meder, P. Duvillard, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, V. Smit; Upfront pathology review in the randomised PORTEC-3 trial for high risk endometrial cancer.

Scientific meeting of the Dutch Society for Radiotherapy and Oncology (NVRO) 2017 (oral presentation)
de Boer, S.M., B.G. Wortman, T. Bosse, M.E. Powell, N. Singh, H. Hollema, G. Wilson, M.N. Chowdhury, L. Mileshkin, J. Pyman, D. Katsaros, S. Carinelli, A. Fyles, C.M. McLachlin, C. Haie-Meder, P. Duvillard, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, V. Smit; The value of upfront pathology review in the PORTEC-3 trial.

American Society of Clinical Oncology (ASCO) annual meeting 2017 (oral presentation)
de Boer, S.M., M.E. Powell, L.R. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A.W. Fyles, M-H. Baron, H.C. Kitchener, H.W. Nijman, R.F.P.M. Kruitwagen, I.M. Jurgenliemk-Schulz, R.A. Nout, V.T.H.B.M. Smit, H. Putter, C.L. Creutzberg; Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.

International Gynecologic Cancer Society (IGCS) biannual meeting 2016 (poster)
de Boer, S.M., B.G. Wortman, T. Bosse, M.E. Powell, N. Singh, H. Hollema, G. Wilson, M.N. Chowdhury, L. Mileshkin, J. Pyman, D. Katsaros, S. Carinelli, A. Fyles, C.M. McLachlin, C. Haie-Meder, P. Duvillard, R.A. Nout, K.W. Verhoeven-Adema, H. Putter, C.L. Creutzberg, V. Smit; Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high risk endometrial cancer.

Dutch Gynaecology Oncology Group symposium 2016 (oral presentation)
de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, R.A. Nout, H.C. Kitchener, P.B. Ottevanger, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, H.W. Nijman, R. Kruitwagen , J.A. Ledermann , K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg; Toxicity and quality of life after adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: first results of the randomised PORTEC-3 trial.

Scientific meeting of the Dutch Society for Radiotherapy and Oncology (NVRO) 2015 (oral presentation)
de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, R.A. Nout, H.C. Kitchener, P.B. Ottevanger, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, H.W. Nijman, R. Kruitwagen , J.A. Ledermann , K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg; Toxicity and quality of life after adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: first results of the randomised PORTEC-3 trial.

European Society Gynaecologic Oncology (ESGO) biannual meeting 2015 (poster)
de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, R.A. Nout, H.C. Kitchener, P.B. Ottevanger, P. Khaw, A. Colombo, A. Fyles, M-H. Baron, H.W. Nijman, R. Kruitwagen , J.A. Ledermann , K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg; Relation between patient and physician reported toxicity in the randomised PORTEC-3 trial of radiation therapy (RT) with or without chemotherapy for endometrial cancer.

European Society Radiation Oncology (ESTRO) annual meeting (poster presentation)
de Boer, S.M., R.A. Nout, H. Putter, I.M. Jürgenliemk-Schulz, J.J. Jobsen, L.C.H.W. Lutgens, E.M. Van der Steen-Banasik, J.W.M. Mens, A. Slot, M.C. Stenfert Kroese, H.W. Nijman, C.L. Creutzberg; Long-term bowel and bladder symptoms after pelvic radiotherapy or vaginal brachytherapy in the PORTEC-2 trial.

CURRICULUM VITAE

Stephanie de Boer werd op 28 november 1986 geboren in Naarden. In 2005 behaalde zij haar Gymnasium diploma aan het Willem de Zwijgercollege te Bussum, waarna zij startte met de studie geneeskunde aan de Universiteit Leiden. Tijdens haar studie heeft zij een klinische stage (interne geneeskunde) gevolgd in het Dr. Moewardi Hospital in Surakarta, Indonesie, en heeft zij haar laatste keuzecoschap tropengeneeskunde in het St Joseph Hospital, Kagondo, Tanzania, afgerond. In 2009 heeft zij wetenschappelijke stage gedaan op de afdeling Cardiologie in het Leids Universitair Medisch Centrum. Na het behalen van haar artsexamen in 2012 (cum laude) heeft ze een jaar in het Bronovo ziekenhuis te Den Haag gewerkt als arts-assistent (ANIOS) op de afdeling interne geneeskunde.

In oktober 2013 is zij gestart met de opleiding tot Radiotherapeut-Oncoloog in het Leids Universitair Medisch Centrum (opleiders: prof. dr. C.A.M. Marijnen en prof dr. C.L. Creutzberg), en gedurende 14 maanden in het Haaglanden Medisch Centrum (opleiders: dr. R. Wiggenraad en dr. A.Y. Verbeek-de Kanter). Tijdens haar opleiding startte zij in 2014 met onderzoek naar de lange termijn kwaliteit van leven in de PORTEC-2 studie en naar de uitkomsten van de PORTEC-3 studie onder begeleiding van prof. dr. C.L. Creutzberg en dr. R.A. Nout. In 2016 heeft zij in het Verenigd Koninkrijk (Barts and the London NHS Trust, London en Manchester Royal Infirmary Hospital, Manchester, begeleider dr. N. Singh) onderzoek gedaan naar de centrale pathologie revisie in de PORTEC-3 studie, waarvoor zij een reisbeurs van het Leids Universiteits Fonds ontving. In het kader van de studies in dit proefschrift bezocht ze diverse congressen in het binnen- en buitenland waar ze meerdere presentaties gaf.

Stephanie zal op 31 december 2019 haar opleiding afronden en zij zal per 1 januari 2020 starten als Radiotherapeut-Oncoloog in het Leids Universitair Medisch Centrum. Dit zal zij blijven combineren met onderzoek binnen de gynaecologiegroep, het PORTEC- en het TransPORTEC consortium.

Stephanie is getrouwd met Jesse Bank en samen hebben zij een dochter, Mila.

DANKWOORD

Allereerst wil ik alle vrouwen bedanken die hebben deelgenomen aan de PORTEC-studies. Zonder hen was dit onderzoek niet mogelijk geweest. Verder wil ik graag alle collega's in het binnen en buitenland bedanken die hebben bijgedragen aan de totstandkoming van de studies in dit proefschrift. De leden van de promotiecommissie bedank ik voor hun kritische blik en tijd.

Without the strong, successful international collaboration the PORTEC-3 trial would never have been possible. Many thanks to the participating groups, their coordinating teams, principal investigators, staff, clinical research teams, the PORTEC-3 data safety monitoring board for all of your support for the PORTEC-3 trial.

Een aantal mensen wil ik graag in het bijzonder bedanken:

Mijn promotor prof dr. C.L. Creutzberg, Carien, voor het vertrouwen en de kans die je mij hebt geboden om dit proefschrift te mogen schrijven en ervaring op te mogen doen in de mooie onderzoeksgroep (trans)PORTEC. Je eindeloze enthousiasme, energie en kennis zijn ongekend, en je laagdrempelige begeleiding waardeer ik enorm.

Mijn co-promotor dr. R.A. Nout, Remi, voor je enthousiaste begeleiding en je kritische blik op het onderzoek.

Prof. dr. H. Putter, Hein, voor je statistische hulp en onderricht, en het maken van de vele mooie figuren.

Dr. K.W. Verhoeven-Adema, Karen, voor alle tijd en energie die je in de PORTEC-3 studie hebt gestoken om de internationale data compleet te krijgen, de prettige samenwerking en je hulp bij de vele queries.

Prof. dr. V.T.H.B.M. Smit en dr. T. Bosse, Vincent en Tjalling, jullie enthousiasme voor de ontwikkelingen binnen de gynaecopathologie is aanstekelijk en motiverend. Bedankt voor al jullie hulp en inspirerende samenwerking: op naar nog vele mooie ontwikkelingen binnen de (trans)PORTEC studies.

Prof. dr. C.A.M. Marijnen, Corrie, voor de kans die je me hebt geboden om gelijktijdig mijn opleiding en promotie onderzoek te mogen doen. Ik heb veel van je geleerd en ik waardeer je adviezen zeer.

Alle collega's van de afdeling radiotherapie, en in het bijzonder de AIOS voor jullie support en de fijne samenwerking.

Mijn (schoon-)familie, vrienden, mijn ouders, Jesse en Mila, voor jullie steun en vertrouwen, maar ook voor de broodnodige ontspanning en afleiding!